Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 389

1.

ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib.

Thunnissen E, Lissenberg-Witte BI, van den Heuvel MM, Monkhorst K, Skov BG, Sørensen JB, Mellemgaard A, Dingemans AMC, Speel EJM, de Langen AJ, Hashemi SMS, Bahce I, van der Drift MA, Looijen-Salamon MG, Gosney J, Postmus PE, Samii SMS, Duplaquet F, Weynand B, Durando X, Penault-Llorca F, Finn S, Grady AO, Oz B, Akyurek N, Buettner R, Wolf J, Bubendorf L, Duin S, Marondel I, Heukamp LC, Timens W, Schuuring EMD, Pauwels P, Smit EF.

Lung Cancer. 2019 Oct 3;138:13-18. doi: 10.1016/j.lungcan.2019.09.023. [Epub ahead of print]

PMID:
31630043
2.

Breast cancer.

Harbeck N, Penault-Llorca F, Cortes J, Gnant M, Houssami N, Poortmans P, Ruddy K, Tsang J, Cardoso F.

Nat Rev Dis Primers. 2019 Sep 23;5(1):66. doi: 10.1038/s41572-019-0111-2. Review.

PMID:
31548545
3.

Correlation of ROS1 Immunohistochemistry With ROS1 Fusion Status Determined by Fluorescence In Situ Hybridization.

Huang RSP, Smith D, Le CH, Liu WW, Ordinario E, Manohar C, Lee M, Rajamani J, Truong H, Li J, Choi C, Li J, Pati A, Bubendorf L, Buettner R, Kerr KM, Lopez-Rios F, Marchetti A, Marondel I, Nicholson AG, Öz AB, Pauwels P, Penault-Llorca F, Rossi G, Thunnissen E, Newell AH, Pate G, Menzl I.

Arch Pathol Lab Med. 2019 Sep 11. doi: 10.5858/arpa.2019-0085-OA. [Epub ahead of print]

PMID:
31509456
4.

TIP60 Inhibitor TH1834 Reduces Breast Cancer Progression in Xenografts in Mice.

Idrissou M, Judes G, Daures M, Sanchez A, El Ouardi D, Besse S, Degoul F, Penault-Llorca F, Bignon YJ, Bernard-Gallon D.

OMICS. 2019 Sep;23(9):457-459. doi: 10.1089/omi.2019.0126. No abstract available.

PMID:
31487234
5.

From Targeting Somatic Mutations to Finding Inherited Cancer Predispositions: The Other Side of the Coin.

Pujol P, De La Motte Rouge T, Penault-Llorca F.

Diagnostics (Basel). 2019 Jul 26;9(3). pii: E83. doi: 10.3390/diagnostics9030083.

6.

Infiltrating and peripheral immune cell analysis in advanced gastric cancer according to the Lauren classification and its prognostic significance.

Pernot S, Terme M, Radosevic-Robin N, Castan F, Badoual C, Marcheteau E, Penault-Llorca F, Bouche O, Bennouna J, Francois E, Ghiringhelli F, De La Fouchardiere C, Samalin E, Baptiste Bachet J, Borg C, Boige V, Voron T, Stanbury T, Tartour E, Gourgou S, Malka D, Taieb J.

Gastric Cancer. 2019 Jul 2. doi: 10.1007/s10120-019-00983-3. [Epub ahead of print]

PMID:
31267360
7.

[GEFPICS' guidelines for management of breast cancer tissue samples in the neoadjuvant setting].

Maran-Gonzalez A, Franchet C, Duprez-Paumier R, Antoine M, Barlier C, Becette V, Berghian A, Blanc-Fournier C, Brabencova E, Charafe-Jauffret E, Chenard MP, Dauplat MM, Delrée P, Fleury C, Garbar C, Ghnassia JP, Haudebourg J, MacGrogan G, Mathieu MC, Michenet P, Penault-Llorca F, Poulet B, Robin Y, Roger P, Russ E, Treilleux I, Valent A, Verriele V, Vincent-Salomon A, Arnould L, Lacroix-Triki M; GEFPICS.

Ann Pathol. 2019 Jun 27. pii: S0242-6498(19)30089-6. doi: 10.1016/j.annpat.2019.04.004. [Epub ahead of print] French.

PMID:
31257035
8.

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E.

Ann Oncol. 2019 Jun 24. pii: mdz189. doi: 10.1093/annonc/mdz189. [Epub ahead of print] No abstract available.

PMID:
31236598
9.

Homoharringtonine, an approved anti-leukemia drug, suppresses triple negative breast cancer growth through a rapid reduction of anti-apoptotic protein abundance.

Yakhni M, Briat A, El Guerrab A, Furtado L, Kwiatkowski F, Miot-Noirault E, Cachin F, Penault-Llorca F, Radosevic-Robin N.

Am J Cancer Res. 2019 May 1;9(5):1043-1060. eCollection 2019.

10.

Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Cardoso F, Kyriakides S, Ohno S, Penault-Llorca F, Poortmans P, Rubio IT, Zackrisson S, Senkus E.

Ann Oncol. 2019 Jun 4. pii: mdz173. doi: 10.1093/annonc/mdz173. [Epub ahead of print] No abstract available.

PMID:
31161190
11.

FOLFOX alone or combined with rilotumumab or panitumumab as first-line treatment for patients with advanced gastroesophageal adenocarcinoma (PRODIGE 17-ACCORD 20-MEGA): a randomised, open-label, three-arm phase II trial.

Malka D, François E, Penault-Llorca F, Castan F, Bouché O, Bennouna J, Ghiringhelli F, de la Fouchardière C, Borg C, Samalin E, Bachet JB, Raoul JL, Miglianico L, Bengrine-Lefèvre L, Dahan L, Lecaille C, Aparicio T, Stanbury T, Perrier H, Cayre A, Laurent-Puig P, Gourgou S, Emile JF, Taïeb J.

Eur J Cancer. 2019 Jul;115:97-106. doi: 10.1016/j.ejca.2019.04.020. Epub 2019 May 23.

PMID:
31129386
12.

[HIPEC in ovarian cancer: What should we expect?]

Picard L, Bourgin C, Penault-Llorca F, Beguinot M, Cornou C, Le Bouedec G, Mouret-Reynier MA, Selle F, Pomel C.

Bull Cancer. 2019 May 21. pii: S0007-4551(19)30193-6. doi: 10.1016/j.bulcan.2019.04.003. [Epub ahead of print] Review. French.

PMID:
31126679
13.

Testing algorithm for identification of patients with TRK fusion cancer.

Penault-Llorca F, Rudzinski ER, Sepulveda AR.

J Clin Pathol. 2019 Jul;72(7):460-467. doi: 10.1136/jclinpath-2018-205679. Epub 2019 May 9. Review.

14.

Analytical validation of a standardised scoring protocol for Ki67 immunohistochemistry on breast cancer excision whole sections: an international multicentre collaboration.

Leung SCY, Nielsen TO, Zabaglo LA, Arun I, Badve SS, Bane AL, Bartlett JMS, Borgquist S, Chang MC, Dodson A, Ehinger A, Fineberg S, Focke CM, Gao D, Gown AM, Gutierrez C, Hugh JC, Kos Z, Laenkholm AV, Mastropasqua MG, Moriya T, Nofech-Mozes S, Osborne CK, Penault-Llorca FM, Piper T, Sakatani T, Salgado R, Starczynski J, Sugie T, van der Vegt B, Viale G, Hayes DF, McShane LM, Dowsett M; International Ki67 in Breast Cancer Working Group of the Breast International Group and North American Breast Cancer Group (BIG-NABCG).

Histopathology. 2019 Aug;75(2):225-235. doi: 10.1111/his.13880. Epub 2019 Jul 8.

PMID:
31017314
15.

The New Synthetic Serum-Free Medium OptiPASS Promotes High Proliferation and Drug Efficacy Prediction on Spheroids from MDA-MB-231 and SUM1315 Triple-Negative Breast Cancer Cell Lines.

Dubois C, Daumar P, Aubel C, Gauthier J, Vidalinc B, Mounetou E, Penault-Llorca F, Bamdad M.

J Clin Med. 2019 Mar 21;8(3). pii: E397. doi: 10.3390/jcm8030397.

16.

Implementing TMB measurement in clinical practice: considerations on assay requirements.

Büttner R, Longshore JW, López-Ríos F, Merkelbach-Bruse S, Normanno N, Rouleau E, Penault-Llorca F.

ESMO Open. 2019 Jan 24;4(1):e000442. doi: 10.1136/esmoopen-2018-000442. eCollection 2019.

17.

A phase Ib dose allocation study of oral administration of lucitanib given in combination with fulvestrant in patients with estrogen receptor-positive and FGFR1-amplified or non-amplified metastatic breast cancer.

Campone M, Bachelot T, Penault-Llorca F, Pallis A, Agrapart V, Pierrat MJ, Poirot C, Dubois F, Xuereb L, Bossard CJ, Guigal-Stephan N, Lockhart B, Andre F.

Cancer Chemother Pharmacol. 2019 Apr;83(4):743-753. doi: 10.1007/s00280-018-03765-3. Epub 2019 Jan 25.

PMID:
30684019
18.

Tumor mutational burden in non-small cell lung cancer-the pathologist's point of view.

Penault-Llorca F, Radosevic-Robin N.

Transl Lung Cancer Res. 2018 Dec;7(6):716-721. doi: 10.21037/tlcr.2018.09.26. Review.

19.

Impact of Chemotherapy-induced Menopause in Women of Childbearing Age With Non-metastatic Breast Cancer - Preliminary Results From the MENOCOR Study.

Passildas J, Collard O, Savoye AM, Dohou J, Ginzac A, Thivat E, Durando X, Kwiatkowski F, Penault-Llorca F, Abrial C, Mouret-Reynier MA.

Clin Breast Cancer. 2019 Feb;19(1):e74-e84. doi: 10.1016/j.clbc.2018.10.003. Epub 2018 Oct 23.

PMID:
30448088
20.

Breaking down the Contradictory Roles of Histone Deacetylase SIRT1 in Human Breast Cancer.

Rifaï K, Idrissou M, Penault-Llorca F, Bignon YJ, Bernard-Gallon D.

Cancers (Basel). 2018 Oct 30;10(11). pii: E409. doi: 10.3390/cancers10110409. Review.

21.

TIP60: an actor in acetylation of H3K4 and tumor development in breast cancer.

Judes G, Dubois L, Rifaï K, Idrissou M, Mishellany F, Pajon A, Besse S, Daures M, Degoul F, Bignon YJ, Penault-Llorca F, Bernard-Gallon D.

Epigenomics. 2018 Nov;10(11):1415-1430. doi: 10.2217/epi-2018-0004. Epub 2018 Oct 16.

PMID:
30324811
22.

Exciting History of Tip60 and Its Companions in Carcinogenesis Across the Heterochromatin Landscapes.

Idrissou M, Rifaï K, Daures M, Penault-Llorca F, Bignon YJ, Bernard-Gallon D.

OMICS. 2018 Sep;22(9):626-628. doi: 10.1089/omi.2018.0122. Epub 2018 Aug 14. No abstract available.

PMID:
30106669
23.

SIRT1-dependent epigenetic regulation of H3 and H4 histone acetylation in human breast cancer.

Rifaï K, Judes G, Idrissou M, Daures M, Bignon YJ, Penault-Llorca F, Bernard-Gallon D.

Oncotarget. 2018 Jul 17;9(55):30661-30678. doi: 10.18632/oncotarget.25771. eCollection 2018 Jul 17.

24.

4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4)†.

Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, Biganzoli L, Boers-Doets CB, Cardoso MJ, Carey LA, Cortés J, Curigliano G, Diéras V, El Saghir NS, Eniu A, Fallowfield L, Francis PA, Gelmon K, Johnston SRD, Kaufman B, Koppikar S, Krop IE, Mayer M, Nakigudde G, Offersen BV, Ohno S, Pagani O, Paluch-Shimon S, Penault-Llorca F, Prat A, Rugo HS, Sledge GW, Spence D, Thomssen C, Vorobiof DA, Xu B, Norton L, Winer EP.

Ann Oncol. 2018 Aug 1;29(8):1634-1657. doi: 10.1093/annonc/mdy192. No abstract available.

25.

The Dilemma of HER2 Double-equivocal Breast Carcinomas: Genomic Profiling and Implications for Treatment.

Marchiò C, Dell'Orto P, Annaratone L, Geyer FC, Venesio T, Berrino E, Verdun di Cantogno L, Garofoli A, Rangel N, Casorzo L, dell'Aglio C, Gugliotta P, Trisolini E, Beano A, Pietribiasi F, Orlassino R, Cassoni P, Pich A, Montemurro F, Mottolese M, Vincent-Salomon A, Penault-Llorca F, Medico E, Ng CKY, Viale G, Sapino A.

Am J Surg Pathol. 2018 Sep;42(9):1190-1200. doi: 10.1097/PAS.0000000000001100.

26.

A new metabolic gene signature in prostate cancer regulated by JMJD3 and EZH2.

Daures M, Idrissou M, Judes G, Rifaï K, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D.

Oncotarget. 2018 May 4;9(34):23413-23425. doi: 10.18632/oncotarget.25182. eCollection 2018 May 4.

27.

The 21-gene Recurrence Score® assay predicts distant recurrence in lymph node-positive, hormone receptor-positive, breast cancer patients treated with adjuvant sequential epirubicin- and docetaxel-based or epirubicin-based chemotherapy (PACS-01 trial).

Penault-Llorca F, Filleron T, Asselain B, Baehner FL, Fumoleau P, Lacroix-Triki M, Anderson JM, Yoshizawa C, Cherbavaz DB, Shak S, Roca L, Sagan C, Lemonnier J, Martin AL, Roché H.

BMC Cancer. 2018 May 4;18(1):526. doi: 10.1186/s12885-018-4331-8.

28.

Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer.

Siena S, Sartore-Bianchi A, Marsoni S, Hurwitz HI, McCall SJ, Penault-Llorca F, Srock S, Bardelli A, Trusolino L.

Ann Oncol. 2018 May 1;29(5):1108-1119. doi: 10.1093/annonc/mdy100.

29.

SIRT1 in Colorectal Cancer: A Friend or Foe?

Rifaï K, Idrissou M, Daures M, Bignon YJ, Penault-Llorca F, Bernard-Gallon D.

OMICS. 2018 Apr;22(4):298-300. doi: 10.1089/omi.2018.0006. Epub 2018 Mar 27. No abstract available.

PMID:
29584552
30.

[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists].

Lantuejoul S, Adam J, Girard N, Duruisseaux M, Mansuet-Lupo A, Cazes A, Rouquette I, Gibault L, Garcia S, Antoine M, Vignaud JM, Galateau-Sallé F, Sagan C, Badoual C, Penault-Llorca F, Damotte D; pour le groupe pathologistes thoraciques de valorisation de l’expertise, de la recherche et de l’innovation (PATTERN). Fondation Synergie Lyon Cancer.

Ann Pathol. 2018 Apr;38(2):110-125. doi: 10.1016/j.annpat.2018.01.007. Epub 2018 Mar 21. French.

PMID:
29571563
31.

High rate of PIK3CA mutations but no TP53 mutations in low-grade adenosquamous carcinoma of the breast.

Bataillon G, Fuhrmann L, Girard E, Menet E, Laé M, Capovilla M, Treilleux I, Arnould L, Penault-Llorca F, Rouzier R, Marchiò C, Bieche I, Vincent-Salomon A.

Histopathology. 2018 Aug;73(2):273-283. doi: 10.1111/his.13514. Epub 2018 May 7.

32.

Physical basis of the 'magnification rule' for standardized Immunohistochemical scoring of HER2 in breast and gastric cancer.

Scheel AH, Penault-Llorca F, Hanna W, Baretton G, Middel P, Burchhardt J, Hofmann M, Jasani B, Rüschoff J.

Diagn Pathol. 2018 Mar 12;13(1):19. doi: 10.1186/s13000-018-0696-x.

33.

Development and validation of a high-performance liquid chromatography method for the quantitation of intracellular PARP inhibitor Olaparib in cancer cells.

Daumar P, Dufour R, Dubois C, Penault-Llorca F, Bamdad M, Mounetou E.

J Pharm Biomed Anal. 2018 Apr 15;152:74-80. doi: 10.1016/j.jpba.2018.01.036. Epub 2018 Jan 31.

PMID:
29414021
34.

Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.

Beguinot M, Dauplat MM, Kwiatkowski F, Lebouedec G, Tixier L, Pomel C, Penault-Llorca F, Radosevic-Robin N.

BMC Cancer. 2018 Feb 3;18(1):129. doi: 10.1186/s12885-018-4013-6.

35.

Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer.

Adam J, Le Stang N, Rouquette I, Cazes A, Badoual C, Pinot-Roussel H, Tixier L, Danel C, Damiola F, Damotte D, Penault-Llorca F, Lantuéjoul S.

Ann Oncol. 2018 Apr 1;29(4):953-958. doi: 10.1093/annonc/mdy014.

PMID:
29351573
36.

Dual SIRT1 expression patterns strongly suggests its bivalent role in human breast cancer.

Rifaï K, Judes G, Idrissou M, Daures M, Bignon YJ, Penault-Llorca F, Bernard-Gallon D.

Oncotarget. 2017 Dec 6;8(67):110922-110930. doi: 10.18632/oncotarget.23006. eCollection 2017 Dec 19.

37.

Guidance Statement On BRCA1/2 Tumor Testing in Ovarian Cancer Patients.

Capoluongo E, Ellison G, López-Guerrero JA, Penault-Llorca F, Ligtenberg MJL, Banerjee S, Singer C, Friedman E, Markiefka B, Schirmacher P, Büttner R, van Asperen CJ, Ray-Coquard I, Endris V, Kamel-Reid S, Percival N, Bryce J, Röthlisberger B, Soong R, de Castro DG.

Semin Oncol. 2017 Jun;44(3):187-197. doi: 10.1053/j.seminoncol.2017.08.004. Epub 2017 Sep 15. Review.

38.

Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines.

Dubois C, Dufour R, Daumar P, Aubel C, Szczepaniak C, Blavignac C, Mounetou E, Penault-Llorca F, Bamdad M.

Oncotarget. 2017 Aug 24;8(56):95316-95331. doi: 10.18632/oncotarget.20517. eCollection 2017 Nov 10.

39.

EZH2 Histone Methyltransferase and JMJD3 Histone Demethylase Implications in Prostate Cancer.

Idrissou M, Daures M, Jemia AB, Judes G, Rifaï K, Penault-Llorca F, Bignon YJ, Guy L, Bernard-Gallon D.

OMICS. 2017 Dec;21(12):751-753. doi: 10.1089/omi.2017.0106. Epub 2017 Nov 21. No abstract available.

PMID:
29161520
40.

TERT promoter status and gene copy number gains: effect on TERT expression and association with prognosis in breast cancer.

Gay-Bellile M, Véronèse L, Combes P, Eymard-Pierre E, Kwiatkowski F, Dauplat MM, Cayre A, Privat M, Abrial C, Bignon YJ, Mouret-Reynier MA, Vago P, Penault-Llorca F, Tchirkov A.

Oncotarget. 2017 Aug 24;8(44):77540-77551. doi: 10.18632/oncotarget.20560. eCollection 2017 Sep 29.

41.

Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer.

Büttner R, Gosney JR, Skov BG, Adam J, Motoi N, Bloom KJ, Dietel M, Longshore JW, López-Ríos F, Penault-Llorca F, Viale G, Wotherspoon AC, Kerr KM, Tsao MS.

J Clin Oncol. 2017 Dec 1;35(34):3867-3876. doi: 10.1200/JCO.2017.74.7642. Epub 2017 Oct 20. Review.

PMID:
29053400
42.

Prospective, multicenter French study evaluating the clinical impact of the Breast Cancer Intrinsic Subtype-Prosigna® Test in the management of early-stage breast cancers.

Hequet D, Callens C, Gentien D, Albaud B, Mouret-Reynier MA, Dubot C, Cottu P, Huchon C, Zilberman S, Berseneff H, Foa C, Salmon R, Roulot A, Lerebours F, Salomon A, Ghali N, Morel P, Li Q, Cayre A, Guinebretière JM, Hornberger J, Penault-Llorca F, Rouzier R.

PLoS One. 2017 Oct 18;12(10):e0185753. doi: 10.1371/journal.pone.0185753. eCollection 2017.

43.

Update on tumor-infiltrating lymphocytes (TILs) in breast cancer, including recommendations to assess TILs in residual disease after neoadjuvant therapy and in carcinoma in situ: A report of the International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Dieci MV, Radosevic-Robin N, Fineberg S, van den Eynden G, Ternes N, Penault-Llorca F, Pruneri G, D'Alfonso TM, Demaria S, Castaneda C, Sanchez J, Badve S, Michiels S, Bossuyt V, Rojo F, Singh B, Nielsen T, Viale G, Kim SR, Hewitt S, Wienert S, Loibl S, Rimm D, Symmans F, Denkert C, Adams S, Loi S, Salgado R; International Immuno-Oncology Biomarker Working Group on Breast Cancer.

Semin Cancer Biol. 2018 Oct;52(Pt 2):16-25. doi: 10.1016/j.semcancer.2017.10.003. Epub 2017 Oct 9. Review.

44.

TIP60 Histone Acetyltransferase in Adipose Tissue: Possible Linkages with Breast Cancer Development?

Judes G, Dubois L, Rifaï K, Daures M, Idrissou M, Bignon YJ, Penault-Llorca F, Bernard-Gallon D.

OMICS. 2017 Nov;21(11):684-686. doi: 10.1089/omi.2017.0117. Epub 2017 Sep 5. No abstract available.

PMID:
28873018
45.

Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Nov;24(6):311-335. doi: 10.1097/PAP.0000000000000161. Review.

46.

Assessing Tumor-infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method From the International Immunooncology Biomarkers Working Group: Part 1: Assessing the Host Immune Response, TILs in Invasive Breast Carcinoma and Ductal Carcinoma In Situ, Metastatic Tumor Deposits and Areas for Further Research.

Hendry S, Salgado R, Gevaert T, Russell PA, John T, Thapa B, Christie M, van de Vijver K, Estrada MV, Gonzalez-Ericsson PI, Sanders M, Solomon B, Solinas C, Van den Eynden GGGM, Allory Y, Preusser M, Hainfellner J, Pruneri G, Vingiani A, Demaria S, Symmans F, Nuciforo P, Comerma L, Thompson EA, Lakhani S, Kim SR, Schnitt S, Colpaert C, Sotiriou C, Scherer SJ, Ignatiadis M, Badve S, Pierce RH, Viale G, Sirtaine N, Penault-Llorca F, Sugie T, Fineberg S, Paik S, Srinivasan A, Richardson A, Wang Y, Chmielik E, Brock J, Johnson DB, Balko J, Wienert S, Bossuyt V, Michiels S, Ternes N, Burchardi N, Luen SJ, Savas P, Klauschen F, Watson PH, Nelson BH, Criscitiello C, O'Toole S, Larsimont D, de Wind R, Curigliano G, André F, Lacroix-Triki M, van de Vijver M, Rojo F, Floris G, Bedri S, Sparano J, Rimm D, Nielsen T, Kos Z, Hewitt S, Singh B, Farshid G, Loibl S, Allison KH, Tung N, Adams S, Willard-Gallo K, Horlings HM, Gandhi L, Moreira A, Hirsch F, Dieci MV, Urbanowicz M, Brcic I, Korski K, Gaire F, Koeppen H, Lo A, Giltnane J, Rebelatto MC, Steele KE, Zha J, Emancipator K, Juco JW, Denkert C, Reis-Filho J, Loi S, Fox SB.

Adv Anat Pathol. 2017 Sep;24(5):235-251. doi: 10.1097/PAP.0000000000000162. Review.

47.

The Epigenetic Landscape of Promoter Genome-wide Analysis in Breast Cancer.

Karsli-Ceppioglu S, Dagdemir A, Judes G, Lebert A, Penault-Llorca F, Bignon YJ, Bernard-Gallon D.

Sci Rep. 2017 Jul 26;7(1):6597. doi: 10.1038/s41598-017-06790-z.

48.

Prospective validation of a lymphocyte infiltration prognostic test in stage III colon cancer patients treated with adjuvant FOLFOX.

Emile JF, Julié C, Le Malicot K, Lepage C, Tabernero J, Mini E, Folprecht G, Van Laethem JL, Dimet S, Boulagnon-Rombi C, Allard MA, Penault-Llorca F, Bennouna J, Laurent-Puig P, Taieb J; PETACC8 Study Investigators; Austrian Breast and Colorectal cancer Study Group (ABCSG); Belgian Group of Digestive Oncology (BGDO); Lone Nørgård Petersen; Fédération Francophone de Cancérologie Digestive (FFCD); Fédération Nationale des Centres de Lutte Contre le Cancer (UNICANCER); Fédération Nationale des Centres de Lutte Contre le Cancer Association Européenne de Recherche en Oncologie (AERO); Arbeitsgemeinschaft Internistische Onkologie (AIO); Gruppo Italiano per lo Studio dei Carcinomi dell'Apparato Digerente (GISCAD); Gruppo Oncologico dell'Italia Meridionale (GOIM); Istituto Oncologico Romagnolo (IOR); Gruppo Cooperativo Chirurgico Italiano (GOCCI); Gruppo Oncologico Nord Ovest (GONO); Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC); Gruppo Cooperativo do Cancro Digestivo da Associação Portuguesa de Investigação Oncológica (GCCD, APIO); Grupo Español para el Tratamiento de los Tumores Digestivos (TTD); John Allen Bridgewater.

Eur J Cancer. 2017 Sep;82:16-24. doi: 10.1016/j.ejca.2017.04.025. Epub 2017 Jun 23.

PMID:
28651158
49.

P-gp expression levels in the erythrocytes of brown trout: a new tool for aquatic sentinel biomarker development.

Valton E, Wawrzyniak I, Amblard C, Combourieu B, Bayle ML, Desmolles F, Kwiatkowski F, Penault-Llorca F, Bamdad M.

Biomarkers. 2017 Sep;22(6):566-574. doi: 10.1080/1354750X.2017.1338314. Epub 2017 Jun 19.

PMID:
28583029
50.

An international reproducibility study validating quantitative determination of ERBB2, ESR1, PGR, and MKI67 mRNA in breast cancer using MammaTyper®.

Varga Z, Lebeau A, Bu H, Hartmann A, Penault-Llorca F, Guerini-Rocco E, Schraml P, Symmans F, Stoehr R, Teng X, Turzynski A, von Wasielewski R, Gürtler C, Laible M, Schlombs K, Joensuu H, Keller T, Sinn P, Sahin U, Bartlett J, Viale G.

Breast Cancer Res. 2017 May 11;19(1):55. doi: 10.1186/s13058-017-0848-z.

Supplemental Content

Loading ...
Support Center